Partners Marc J. Ross and James M. Turner Represent Tonix Pharmaceuticals in $10 Million Public Offering of Common Stock
Press Release – New York, NY – June 23, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a developer of next-generation medicines for common disorders of the central nervous system,
including fibromyalgia and post-traumatic stress disorder, in an underwritten public offering of 5,000,000 shares of its common stock. The shares were sold at a purchase price of $2.00 per share. Tonix raised $10 million in gross proceeds. Roth Capital Partners and National Securities Corporation, a wholly-owned subsidiary of National Holdings, Inc. (NASDAQ:NHLD), acted as joint book-running managers for the offering.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Marc J. Ross and James M. Turner and associate Nazia Khan.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Quest Solutions, Inc. in $5 Million Private Placement - April 10, 2019
- Sichenzia Ross Ference LLP Congratulates INmune Bio Inc., on Initial Public Offering - April 10, 2019
- FDA sets first hearing on CBD in May as the agency looks at legalizing the cannabis compound in food and drinks - April 4, 2019